Skip to content

Clinical trial of emergency rescue of absolute glaucoma patients with corneal pathway one-way aqueous humor drainage device

Clinical trial of emergency rescue of absolute glaucoma patients with corneal pathway one-way aqueous humor drainage device

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114593
Enrollment
Unknown
Registered
2025-12-15
Start date
2023-05-16
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glaucoma

Interventions

Treatment group:Implant a "corneal path unidirectional aqueous humor drainage device" in the surgical eyes.

Sponsors

Beijing Tongren Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with absolute stage glaucoma whose intraocular pressure remains above 21mmHg after various drug treatments and multiple surgeries. 2. All current clinical treatment methods are no longer capable of controlling the patient's eye condition. 3. Age between 18 and 75 years old. 4. Understand and voluntarily undergo the corresponding surgical treatment, and be able to understand and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with poor overall immunity, such as those who have recently undergone chemotherapy due to systemic diseases. 2. The eye to be operated on is complicated with ocular inflammatory lesions, such as conjunctivitis, meibomian adenitis, dacryocystitis, uveitis, etc. 3. Corneal lesions of the intended surgical eye, such as keratitis, corneal edema, corneal decompensation, keratoconus, etc. 4. The eye to be operated on is complicated with diseases that can cause increased orbital pressure, such as orbital tumors, thyroid-associated ophthalmopathy, etc. 5. Within half a year, the operated eye was complicated with corneal trauma, such as corneal foreign body, corneal laceration, etc. 6. Patients who are unable to sign the informed consent form for various reasons.

Design outcomes

Primary

MeasureTime frame
intraocular pressure, IOP;

Secondary

MeasureTime frame
Corneal Endothelial Cell Count;

Countries

China

Contacts

Public ContactNingli Wang

Beijing Tongren Hospital

wningli@vip.163.com+86 10 5826 5900

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026